Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Valentina RossiBerchialla PaolaDiana GiannarelliCecilia NisticòGianluigi FerrettiSimona GasparroMichelangelo RussilloGiovanna CataniaLeonardo VignaRossella Letizia MancusiEmilio BriaFilippo MontemurroFrancesco CognettiAlessandra FabiPublished in: Cancers (2019)
CDK 4/6 inhibitors have similar efficacy when associated with an AI in the first-line treatment of HR+ MBC, and are superior to either F or AI monotherapy, regardless of any other patients or tumor characteristics.